Drug intelligence / Profile preview

V5

Development stage: Unknown
Lead developer: Immunitor
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

V5 is a patented immunotherapeutic oral vaccine technology platform developed by Immunitor Inc. It has demonstrated clinical effectiveness against chronic hepatitis B, chronic hepatitis C, and tuberculosis, including multi-drug resistant forms and TB/HIV co-infection. The platform has also shown potential for applications in non-infectious diseases such as cancer and autoimmune disorders. V5 completed Phase II clinical trials for hepatitis B and C.

Beyond the preview

Go deeper on V5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V5.

Explore the full profile